Although the above trials have shown promising efficacy of osimertinib in patients with EGFR T790M-positive advanced NSCLC, further evaluation is warranted through a real-world study that will help clinicians gain more effectiveness and safety profile in a large, varied patient population. Here, EGFR is linked to non-small cell lung carcinoma.